Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, In Vivo investigates.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec in diam ut dolor malesuada congue vel non ligula. Quisque eget...
Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, In Vivo investigates.
The E in ESG: SUDs, reuse, disposables, refurbishing, reprocessed devices? Multiple panelists at the 2024 MedTech Forum addressed the role medtech manufacturers should have in the climate change challenge.
Record attendance at the 2024 MedTech Forum in Vienna heard industry leaders voice optimism grounded in realism about future developments for Europe’s medtech industry, markets and delivery of care to patients. In Vivo filtered out 16 trends to watch.
Leadership succession is proceeding within South Korean pharmaceutical corporations such as Daiichi Sankyo Korea, Astellas Pharma Korea, Kyowa Kirin Korea as well as MSD Korea.
Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, In Vivo investigates.
Christopher Anzalone is spearheading Arrowhead Pharmaceuticals' transformation from a development-focused to a commercial-stage biotech. The CEO touts an “almost plug and play” platform, a derisked development strategy and a busy pipeline with vast potential.
Christopher Anzalone is spearheading Arrowhead Pharmaceuticals' transformation from a development-focused to a commercial-stage biotech. The CEO touts an “almost plug and play” platform, a derisked development strategy and a busy pipeline with vast potential.
